112 Ces Urol 2024; 28(2): 105–112 ORIGINÁLNÍ PRÁCE 3. Babjuk M, Burger M, Capoun O, et al. European Association of Urology Guidelines on Non‑muscle ‑invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol. 2022 Jan; 81(1): 75–94. doi: 10.1016/j. eururo.2021.08.010. Epub 2021 Sep 10. PMID: 34511303. 4. Schwaibold HE, Sivalingam S, May F, Hartung R. The value of a second transurethral resection for T1 bladder cancer. BJU Int. 2006 Jun; 97(6): 1199–201. doi: 10.1111/j.1464-410X.2006.06144.x. Epub 2006 Mar 23. PMID: 16566814. 5. Cumberbatch MGK, Foerster B, Catto JWF, et al. Repeat Transurethral Resection in Non‑muscle‑invasive Bladder Cancer: A Systematic Review. Eur Urol. 2018 Jun; 73(6): 925–933. 6. Lin L, Guo X, Ma Y, et al. Does repeat transurethral resection of bladder tumor influence the diagnosis and prognosis of T1 bladder cancer? A systematic review and meta‑analysis. Eur J Surg Oncol. 2023 Jan; 49(1): 29–38. doi: 10.1016/j.ejso.2022.06.005. Epub 2022 Jun 13. PMID: 35752497. 7. Blindheim AJ, Fosså SD, Babigumira R, Andreassen BK. The use of reTURB in T1 bladder cancer: a Nor‑ wegian population‑based study. Scand J Urol. 2021 Aug; 55(4): 268–274. 8. Soria F, D‘Andrea D, Moschini M, et al. Predictive factors of the absence of residual disease at repeated transurethral resection of the bladder. Is there a possibility to avoid it in well‑selected patients? Urol Oncol. 2020 Mar; 38(3): 77.e1–77.e7. 9. Dalbagni G, Vora K, Kaag M, et al. Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. Eur Urol. 2009 Dec; 56(6): 903–10. doi: 10.1016/j.eururo.2009.07.005. Epub 2009 Jul 17.
RkJQdWJsaXNoZXIy NDA4Mjc=